XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Significant Accounting Policies (Tables)
6 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
Total collaborative research and development revenue and royalty income from customers that accounted for greater than 10% of total revenues for the six months ended December 31, 2018 and for the years ended June 30, 2018, 2017 and 2016 are summarized in the following table:
 
 
Six Months Ended
 
 
 
 
 
 
 
 
 
 
 
 
December 31,
 
 
Year Ended June 30,
 
Customer / Category
 
2018
 
 
2018
 
 
2017
 
 
2016
 
Ocumension Therapeutics
 
 
59
%
 
 
*
 
 
 
*
 
 
 
*
 
Alimera Sciences
 
 
21
%
 
 
24
%
 
 
*
 
 
 
14
%
Bausch & Lomb
 
 
16
%
 
 
35
%
 
 
13
%
 
 
77
%
Feasibility studies
 
 
*
 
 
 
36
%
 
 
*
 
 
 
*
 
Pfizer
 
 
*
 
 
 
*
 
 
 
74
%
 
 
*
 
 
 
*
Less than 10%
 
 
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares
Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:
 
 
 
Six Months
 
 
 
 
 
 
 
 
 
 
 
 
Ended
 
 
 
 
 
 
 
 
 
 
 
 
December 31,
 
 
Year Ended June 30,
 
 
 
2018
 
 
2018
 
 
2017
 
 
2016
 
Stock options
 
 
8,139,377
 
 
 
7,750,244
 
 
 
6,895,685
 
 
 
4,981,421
 
Warrants
 
 
486,812
 
 
 
20,671,036
 
 
 
623,605
 
 
 
623,605
 
Restricted stock units
 
 
1,090,213
 
 
 
1,398,129
 
 
 
948,500
 
 
 
 
Performance stock units
 
 
370,000
 
 
 
466,668
 
 
 
210,000
 
 
 
 
Deferred stock units
 
 
35,418
 
 
 
35,001
 
 
 
 
 
 
 
 
 
 
10,121,820
 
 
 
30,321,078
 
 
 
8,677,790
 
 
 
5,605,026